View Report
September 29, 2025
Batch: CJCND8
Measured Result 4.78 mg 95.6% of label claim
Peptide Hubs
Peptide Hubs
Latest Laboratory Result 4.78 mg September 29, 2025 · 95.6% of label claim View
You will save $22.00
CJC-1295 No DAC 5 mg
Product Information Compound Details
Active Substance Mod GFR 1-29 Modified GRF (1-29) / CJC-1295 without DAC
5 mg/vialStrength 5 mg/vial
Package 1 Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer Peptide Hubs
$33.00
$55.00
Shipping :
International
U.S. Domestic
Product Overview
CJC-1295 No DAC 5 mg by Peptide Hubs
CJC-1295 No DAC 5 mg is a lyophilized modified growth hormone-releasing factor research product manufactured by Peptide Hubs and supplied as a 5 mg/vial powder in a 2 mL vial.
Mod GFR 1-29 Injectable
CJC-1295 No DAC 5 mg contains Modified GRF (1-29), also known as Mod GRF 1-29 or CJC-1295 without DAC. This synthetic peptide is a tetra-substituted analog of growth hormone-releasing hormone (GHRH), consisting of the first 29 amino acids of the native hormone with four strategic substitutions designed to resist enzymatic degradation. The four substitutions—D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27—enhance stability against dipeptidyl peptidase-4 (DPP-4) and other peptidases.
Unlike CJC-1295 with DAC (Drug Affinity Complex), this no-DAC version lacks the albumin-binding moiety that extends half-life to days. Mod GRF 1-29 has a short half-life of approximately 25-30 minutes, producing a discrete growth hormone pulse that more closely mimics the body's natural pulsatile GH secretion pattern. The peptide acts by binding to GHRH receptors on the anterior pituitary, activating cAMP-dependent signaling pathways that stimulate GH synthesis and release.
In non-medical bodybuilding and research contexts, CJC-1295 No DAC is commonly referenced for its potential to stimulate endogenous GH release, often in combination with ghrelin receptor agonists such as ipamorelin for synergistic effects. However, CJC-1295-related substances have not been approved by the FDA for any indication, and the agency has raised significant concerns regarding their safety and characterization.
Key Benefits of CJC-1295 No DAC 5 mg
- Tetra-substituted GHRH analog with enhanced enzymatic stability
- Short half-life supports pulsatile GH release research
- Lyophilized powder format for reconstitution flexibility
- Commonly combined with ipamorelin in research protocols
- Manufactured by Peptide Hubs
Formulation
Lyophilized Powder
CJC-1295 No DAC 5 mg is supplied as a lyophilized (freeze-dried) powder in a 2 mL vial. Reconstitution with an appropriate solvent is required before use in research contexts.
Product Profile
Mod GFR 1-29 Profile
Mod GRF 1-29 is a 29-amino-acid peptide with a molecular weight of approximately 3,367.9 g/mol and the molecular formula C₁₅₂H₂₅₂N₄₄O₄₂.
GHRH Analog
Mod GRF 1-29 belongs to the class of growth hormone-releasing hormone (GHRH) analogs, which stimulate GH secretion through direct activation of pituitary GHRH receptors. This mechanism is distinct from ghrelin receptor agonists such as ipamorelin or GHRP-6, which act through a different receptor pathway.
The four amino acid substitutions in Mod GRF 1-29 are specifically designed to address stability limitations of native GHRH(1-29). The D-Ala substitution at position 2 confers resistance to DPP-4 cleavage, while the Gln at position 8 prevents asparagine deamidation. The Ala at position 15 and Leu at position 27 further enhance peptide stability and bioactivity. These modifications result in a peptide that, while still short-acting, is more resistant to rapid degradation than the unmodified fragment.
In non-medical bodybuilding contexts, Mod GRF 1-29 is commonly referenced for stimulating pulsatile GH release, with users typically dosing multiple times daily to mimic natural GH rhythms. The Frontiers in Endocrinology review notes that claims about CJC-1295 without DAC rest on extrapolation rather than direct human data, and clinicians should treat exposure to these compounds as evidence-poor.
Defining Characteristic
Short Half-Life for Pulsatile Release
Mod GRF 1-29 is distinguished by its short half-life of approximately 25-30 minutes, which produces a discrete GH pulse rather than sustained elevation. This contrasts with CJC-1295 with DAC, which has a half-life of up to 8 days and produces more sustained GH and IGF-1 elevation.
CJC-1295 No DAC 5 mg vs Other Peptide Hubs Preparations
Peptide Hubs offers several research peptides targeting growth hormone pathways. Within this lineup, Ipamorelin is commonly discussed alongside Mod GRF 1-29 for its synergistic GH-releasing properties, acting through the ghrelin receptor rather than the GHRH receptor.
For a combined GHRH and GHRP product, CJC-1295/Ipamorelin represents a pre-mixed blend, while Tesamorelin is a longer-acting GHRH analog with FDA approval for a specific medical indication. For research requiring a reconstitution solution, Bacteriostatic Water is the standard diluent for preparing lyophilized peptides like CJC-1295 No DAC 5 mg.
Laboratory Testing
CJC-1295 No DAC 5 mg Lab Reports
Published laboratory reports for CJC-1295 No DAC 5 mg are shown below with the test date, measured content, and batch number.
View Report
Laboratory results apply to the specific tested sample represented in each published report and should not be interpreted as a measurement of every vial or production batch.
Dosage & Usage
CJC-1295 No DAC 5 mg Dosage & Usage
The information below is provided for educational reference only. CJC-1295 No DAC is not an FDA-approved human drug. Its use for any non-medical purpose falls outside approved indications, and no established human dosing regimen exists.
Typical Dosage Ranges
Because Mod GRF 1-29 lacks FDA approval and published human dose-finding trials for its intended research applications, there is no medically established dosage range. In non-medical bodybuilding and research communities, reference ranges are derived from community convention. Commonly referenced ranges are 100–300 mcg per injection, administered 1–3 times daily.
| Use Case | Common Reference Range | Injection Frequency |
|---|---|---|
| Standard protocol (non-medical) | 100–200 mcg | 1–3 times daily |
| Combined with ipamorelin (non-medical) | 100–200 mcg CJC + 100–200 mcg IPA | 1–2 times daily |
| Upper range (non-medical) | 300 mcg | Once daily |
Community protocols commonly reference dosing in a fasted state, typically before bed and/or post-workout to align with natural GH pulses.
Reconstitution & Handling
CJC-1295 No DAC 5 mg is supplied as a lyophilized powder and requires reconstitution before use. A 5 mg vial reconstituted with 2 mL of solvent yields a concentration of 2.5 mg/mL (2,500 mcg/mL), meaning a 100 mcg dose would require drawing 0.04 mL (4 units on a U-100 insulin syringe).
Reconstituted solution should be stored refrigerated at 2–8°C and protected from light. Avoid repeated freeze-thaw cycles.
Stacking & Cycle Considerations
In non-medical bodybuilding contexts, Mod GRF 1-29 is frequently combined with Ipamorelin for synergistic GH release, as the two peptides target different receptors—the GHRH receptor and the ghrelin receptor, respectively. Cycle lengths commonly referenced range from 8 to 12 weeks on, followed by a 4-week break.
For research requiring a pre-mixed combination, CJC-1295/Ipamorelin offers a convenient alternative, though the ratio and concentration differ from self-prepared blends.
Important
Individual Response Varies
No human dose-response data for therapeutic outcomes exists for CJC-1295 No DAC. All dosage information is derived from community convention and should not be interpreted as medical guidance.
Safety & Information
Mod GFR 1-29 Safety Information
CJC-1295 No DAC is not FDA-approved for any human use. The FDA has evaluated CJC-1295-related bulk drug substances and found that available safety and characterization data are insufficient to support compounding.
Important Safety Information
The FDA has raised significant concerns about CJC-1295-related substances, including the no-DAC form. The agency noted that CJC-1295 (free base) is not well-characterized due to inconsistent naming conventions and absent critical data on impurities, aggregates, and endotoxins. Injectable routes of administration present particular immunogenicity risks due to potential peptide aggregation and impurities.
Elevated GH and IGF-1 levels carry known risks, including those listed in FDA-approved recombinant human growth hormone product labeling. The FDA noted it has not identified data suggesting CJC-1295-related substances would not present similar risks.
Important
Non-Medical Use
CJC-1295 No DAC is marketed as a research peptide and has been identified in unknown pharmaceutical preparations seized by authorities. It is on the WADA Prohibited List under S2. Non-medical use falls outside approved indications.
Potential Adverse Effects
Clinical studies of CJC-1295 with DAC (a related but distinct compound) reported injection site reactions in approximately 70% of subjects after a single dose and in all subjects after multiple doses. Other reported effects included headache, diarrhea, flushing, nausea, abdominal pain, transient dizziness, hypotension, and increased heart rate.
A phase 2 clinical trial of CJC-1295 DAC was terminated in 2006 following the death of a subject who experienced an acute myocardial infarction approximately 2 hours after receiving an 11th weekly dose. The attending physician attributed the event to asymptomatic coronary artery disease with plaque rupture and occlusion.
Community discussions of CJC-1295 No DAC mention potential water retention, joint stiffness, and numbness/tingling in extremities, though these reports are anecdotal.
Conditions Requiring Medical Evaluation
Given the absence of comprehensive human safety data for CJC-1295 No DAC, any consideration of its use should involve consultation with a qualified healthcare professional. Individuals with a history of cancer or strong family history of malignancy should exercise particular caution due to the theoretical risks of elevated IGF-1.
Monitoring During Use
No established monitoring protocol exists for non-medical CJC-1295 No DAC use. Clinicians evaluating patients using GH-related peptides should consider monitoring IGF-1 levels, blood glucose, and potential injection site reactions.
Product Care
Storage & Handling
Store lyophilized powder at -20°C, sealed, dry, and protected from light. Once reconstituted, store refrigerated at 2–8°C and use within the recommended timeframe. Avoid repeated freeze-thaw cycles. Keep out of reach of children.
Further Safety Information
Shipping & Authenticity
Shipping & Product Authenticity
CJC-1295 No DAC 5 mg is supplied through the official Peptide Hubs distribution chain and shipped in original manufacturer packaging with discreet handling.
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with privacy-focused handling. Products are supplied through the official Peptide Hubs distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your CJC-1295 No DAC 5 mg product, use the security code on the vial label and cross-check it on the Peptide Hubs official site. Original packaging and manufacturer presentation help reinforce product legitimacy.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Storage
CJC-1295 No DAC 5 mg Storage
Proper storage conditions help preserve peptide stability and integrity throughout shelf life.
Recommended Conditions
Store lyophilized powder at -20°C, sealed, dry, and protected from light. Under these conditions, the dry powder is stable for up to 24 months.
Once reconstituted, store refrigerated at 2–8°C and use within the recommended timeframe. Avoid repeated freeze-thaw cycles to maintain peptide integrity.
Keep out of reach of children. Follow proper handling practices.
Quick Reference
Do & Don't
- Do store powder at -20°C, sealed and protected from light
- Do keep in original packaging until use
- Do refrigerate reconstituted solution at 2–8°C
- Don't expose to excessive heat or moisture
- Don't subject to repeated freeze-thaw cycles
- Don't use if solution appears cloudy or contains particles
Frequently Asked Questions
CJC-1295 No DAC 5 mg FAQ
Answers to common questions about CJC-1295 No DAC 5 mg, Mod GRF 1-29, and research peptide handling.
What is CJC-1295 No DAC 5 mg used for?
CJC-1295 No DAC 5 mg contains Modified GRF (1-29), a GHRH analog studied for its potential to stimulate endogenous growth hormone release. In non-medical bodybuilding contexts, it is commonly referenced for GH pulse stimulation and recovery support, though such use falls outside approved indications.
How often should CJC-1295 No DAC 5 mg be injected?
No established human dosing schedule exists. Community protocols commonly reference 1–3 daily subcutaneous injections due to the short half-life of approximately 25-30 minutes.
Does CJC-1295 No DAC 5 mg require PCT?
CJC-1295 No DAC does not suppress endogenous testosterone production and does not require post-cycle therapy in the way anabolic steroids do. However, any non-medical peptide use should be approached with caution given the absence of comprehensive human safety data.
What does Mod GRF 1-29 do?
Mod GRF 1-29 is a synthetic GHRH analog that binds to GHRH receptors on the anterior pituitary, stimulating growth hormone synthesis and release through cAMP-dependent signaling pathways.
How long does CJC-1295 No DAC take to work?
Pharmacokinetically, Mod GRF 1-29 has a short half-life of approximately 25-30 minutes, producing a discrete GH pulse after administration. Community reports suggest sleep quality and recovery improvements may appear over 1–3 weeks of consistent use.
Is Mod GRF 1-29 the best GHRH analog?
There is no universally “best” GHRH analog. Mod GRF 1-29 produces a pulsatile GH release due to its short half-life, which some describe as more physiologic, while longer-acting analogs such as CJC-1295 with DAC produce sustained elevation.
What is the difference between CJC-1295 No DAC 5 mg and Ipamorelin?
Mod GRF 1-29 acts through the GHRH receptor, while Ipamorelin acts through the ghrelin receptor. They target different pathways and are sometimes combined for synergistic GH release in non-medical protocols, but they are not interchangeable.
What is the difference between CJC-1295 No DAC 5 mg and CJC-1295 with DAC?
CJC-1295 No DAC lacks the Drug Affinity Complex that extends half-life, resulting in a short half-life of approximately 25-30 minutes. CJC-1295 with DAC has a half-life of up to 8 days, requiring only 1–2 injections per week but producing more sustained GH and IGF-1 elevation.
Is 300 mcg of CJC-1295 No DAC a lot?
300 mcg is at the upper end of the range commonly referenced in community protocols (100–300 mcg per injection). The GH response to GHRH analogs is described as saturable, meaning higher doses do not necessarily produce proportionally greater effects.
What strength is CJC-1295 No DAC 5 mg?
CJC-1295 No DAC 5 mg is labeled at 5 mg of Mod GRF 1-29 per vial. It is supplied as a lyophilized powder in a 2 mL vial.
Is CJC-1295 No DAC 5 mg lab tested?
Yes. A published laboratory report dated September 29, 2025 measured CJC-1295 No DAC 5 mg at 4.78 mg, equivalent to 95.6% of its 5 mg label claim. The batch number is CJCND8.
How should CJC-1295 No DAC 5 mg be stored?
Store the lyophilized powder at -20°C, sealed, dry, and protected from light. Once reconstituted, refrigerate at 2–8°C and use within the recommended timeframe. Avoid repeated freeze-thaw cycles.
Related Offers
Lab Tested
Domestic & International
-40% OFF
Peptide Hubs
Product Information Compound Details
Active Substance Ipamorelin Selective growth hormone secretagogue (pentapeptide)
5 mg/vialStrength 5 mg/vial
Package 1 Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer Peptide Hubs
$26.40
$44.00
Lab Tested
Domestic & International
-40% OFF
Peptide Hubs
Product Information Compound Details
Active Formula TB 500 / BPC 157 Blend
10 mg/vialThymosin Beta 4 (TB-500 fragment) 5 mg
Body Protection Compound 157 5 mg
Total Strength 10 mg/vial
Package 1 Vial 2 mL vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer Peptide Hubs
$45.00
$75.00
Lab Tested
Domestic & International
-40% OFF
Peptide Hubs
Product Information Compound Details
Active Substance Pentadecapeptide BPC 157 (Body Protection Compound)
5 mg/vialStrength 5 mg/vial
Package 1 Vial
Form Lyophilized Powder
Vial Size 2 mL Vial
Drug Class Research Peptide
Manufacturer Peptide Hubs
$22.80
$38.00